ArticleResearch and practice in thrombosis and haemostasis2025
Haemostasis alterations in immune thrombocytopenia and their clinical significance.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fifteen years of pediatric immune thrombocytopenia in a national cohort: chronicity, diagnostic challenges, and treatment patterns-single center experience.Frontiers in pediatrics · 2026Article
- Correlation between the CD8Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is highly heterogeneous, and only a subset of patients with severe thrombocytopenia develops significant bleeding. ITP is also associated with a paradoxical increased risk of thrombosis. Here, we review the multiple haemostasis alterations reported in patients with ITP. Data show an increased platelet basal activation with lower platelet reactivity but with overall increased platelet function. The activated state of platelets and the endothelial dysfunction lead to an activation of coagulation. These alterations tend to counterbalance the bleeding tendency related to thrombocytopenia but have some variability among patients. Consequently, several functional assays have correlated the magnitude of haemostasis alterations to bleeding risk. These results suggest that ITP is a multifaceted bleeding disorder that goes beyond simple thrombocytopenia. The heterogeneity in the various alterations in haemostatic function is likely to drive the variable bleeding phenotypes observed. Haemostasis functional assays could thus serve as clinically relevant tools to individualize management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.